<DOC>
	<DOCNO>NCT02639182</DOCNO>
	<brief_summary>The purpose study evaluate progression free survival ( PFS ) , base investigator radiologic review , AGS-16C3F compare axitinib subject metastatic renal cell carcinoma .</brief_summary>
	<brief_title>A Study AGS-16C3F vs. Axitinib Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>Histologically confirm diagnosis metastatic RCC Nonclear subject must ENPP3 positive , define IHC Hscore ≥15 Has evidence progression last regimen receive : Clear cell subject : must receive least 2 prior systemic regimen , one antiVEGF agent . Nonclear cell subject : must receive least one prior antiVEGF regimen Has measurable disease accord Response Criteria Solid Tumors ( RECIST v.1.1 ) Has Eastern Cooperative Group ( ECOG ) performance status 0 1 Has accessible archive tumor tissue primary tumor metastatic site ( exclude bone ) , least 5 tumor tissue section ( 4 micron ) provide study . If archive tissue available , biopsy may perform obtain tissue . Has adequate organ function include : Hematopoietic function follow : 1 . Absolute neutrophil count ( ANC ) ≥ 1.5 x 10 9/L 2 . Platelet count ≥ 100 x 10 9/L 3 . Hemoglobin ≥ 9 g/dL ( transfusion allow ) Renal Function follow : 1 . Creatinine ≤ 1.5 x upper limit normal ( ULN ) , calculate glomerular filtration rate ( GFR ) &gt; 40 mL/min ( CockcroftGault ) creatinine &gt; 1.5x ULN Hepatic function , follow : 1 . Aspartate aminotransferase ( AST ) Alanine aminotransferase ( ALT ) ≤ 2.5 x ULN ≤ 5x ULN know liver metastases 2 . Total bilirubin ≤ 1.5 x ULN Prothrombin time ( PT ) activate partial thromboplastin time ( aPTT ) level ≤1.5 x ULN If subject receive Coumadin ( warfarin ) , stable international normalization ratio ( INR ) 23 require . No clinical symptom hypothyroidism Urine Protein Creatinine Ratio ( uPCR ) &lt; 2.0 If uPCR ≥ 2.0 24hour urine collection perform qualify . This result must &lt; 2 g per 24 hour . Female subject must either : Be nonchildbearing potential : 1. postmenopausal ( define least 1 year without menses ) prior Screening , 2. document surgically sterile Or , childbearing potential , 1 . Agree try become pregnant study 28 day final study drug administration 2 . And negative serum pregnancy test ≤ 10 day cycle 1 , day 1 ( C1D1 ) And , heterosexually active , agree consistently use 2 form highly effective birth control* ( least one must barrier method ) start Screening throughout study period 28 day final study drug administration . Female subject must agree breastfeed start Screening throughout study period , 28 day final study drug administration . Female subject must donate ovum start Screening throughout study period , 28 day final study drug administration . Male subject female spouse/partners childbearing potential must use highly effective contraception* consist 2 form birth control ( least one must barrier method ) start Screening continue throughout study period , 90 day final study drug administration Male subject must donate sperm start Screening throughout study period , 90 day final study drug administration Note : *Highly effective form birth control include : Consistent correct usage establish oral contraception . Established intrauterine device ( IUD ) intrauterine system ( IUS ) . Barrier method contraception : condom occlusive cap ( diaphragm cervical/vault cap ) spermicidal foam/gel/film/cream/suppository Has previously treat axitinib , AGS16C3F , AGS16M8F Has untreated brain metastasis . In case solitary brain metastasis resect , must evidence diseasefree interval least 3 month postsurgery . For brain metastasis treat whole brain stereotactic radiation therapy , brain imaging must stable &gt; 3 month . All subject previously treat brain metastasis must stable corticosteroid therapy least 28 day . Has uncontrolled hypertension define blood pressure &gt; 150/90 medication ( ) 2 blood pressure read take least 1 hour apart ; 2 concurrent antihypertensive medication control blood pressure enrollment permit . Has gastrointestinal abnormality include : inability take oral medication ; requirement intravenous alimentation ; prior surgical procedure affect absorption include total gastric resection ; active gastrointestinal bleeding , unrelated cancer , evidence hematemesis , hematochezia melena past 3 month without evidence resolution document endoscopy colonoscopy ; malabsorption syndromes celiac disease , cystic fibrosis , inflammatory bowel disease , systemic sclerosis , carcinoid syndrome Has ocular condition : Active infection corneal ulcer Monocularity Visual acuity 20/70 bad eye History corneal transplantation Contact lens dependent ( use contact lens , must able switch glass entire study duration ) Uncontrolled glaucoma ( topical medication allow ) Uncontrolled evolve retinopathy , wet macular degeneration , uveitis , papilledema , optic disc disorder Has use investigational drug ( include market drug approve indication ) within 2 week prior date Screening . No time limit applies use market drug approve indication provide subject progressed treatment toxicity attributable drug resolve , return baseline stabilize . Has know sensitivity ingredient : investigational product AGS16C3F and/or , Inlyta® ( axitinib ) and/or , 1 % prednisolone acetate ophthalmic suspension corticosteroid . Is currently use ( i.e. , within 14days prior first dose ) drug know strong CYP3A4/5 inhibitor / inducer . Has history thromboembolic event ( e.g. , deep vein thrombosis [ DVT ] pulmonary embolism [ PE ] ) ≤ 6 month C1D1 Has history bleed disorder ( e.g. , pulmonary hemorrhage , significant hemoptysis , menometrorrhagia respond hormonal treatment ) ≤ 2 month C1D1 Has active angina Class III IV Congestive Heart Failure ( New York Heart Association CHF Functional Classification System ) clinically significant cardiac disease within 6 month randomization , include myocardial infarction , unstable angina , Grade 2 great peripheral vascular disease , congestive heart failure , arrhythmia control medication . Had major surgery ≤ 4 week C1D1 Is pregnant ( confirm positive serum pregnancy test ) lactating Has active infection require treatment systemic ( intravenous oral ) antiinfectives ( antibiotic , antifungal , antiviral agent ) ≤ 10 day C1D1 Is unwilling unable comply study requirement Has medical psychiatric disorder compromise ability subject give write informed consent , and/or comply study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Axitinib</keyword>
	<keyword>Metastatic Renal Cell Carcinoma</keyword>
	<keyword>AGS-16C3F</keyword>
</DOC>